KURA
Kura Oncology, Inc.
$10.42
-0.12
(-1.13%)
Mkt Cap
930.64M
Volume
397,924
52W Range
5.45-12.49
Sector
Healthcare
Beta
0.35
EPS (TTM)
-3.35
P/E Ratio
-3.27
Revenue (TTM)
71.64M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.48M | 53.88M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (278.67M) | (173.98M) | (152.63M) | (135.84M) | (130.47M) | (89.62M) | (63.14M) | (60.45M) | (35.43M) | (27.56M) | (22.62M) | (11.01M) |
| EPS | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -2.69 |
| Free Cash Flow | (70.70M) | 133.84M | (124.99M) | (110.69M) | (105.70M) | (72.00M) | (54.76M) | (48.66M) | (28.44M) | (25.35M) | (17.99M) | (2,631) |
| FCF / Share | -0.81 | 1.55 | -1.71 | -1.65 | -1.59 | -1.36 | -1.31 | -1.38 | -1.22 | -1.36 | -1.81 | -0.00 |
| Operating CF | (64.06M) | 134.32M | (124.82M) | (110.06M) | (104.55M) | (69.83M) | (54.76M) | (48.66M) | (28.44M) | (25.35M) | (17.93M) | (2,547) |
| Total Assets | 738.36M | 760.16M | 448.94M | 456.31M | 534.05M | 647.21M | 241.97M | 182.38M | 95.85M | 69.82M | 87.26M | 1.38M |
| Total Debt | 20.46M | 16.59M | 17.20M | 14.02M | 6.88M | 14.98M | 7.75M | 7.50M | 7.10M | 7.32M | 0 | 2.53M |
| Cash & Equiv | 149.10M | 224.46M | 37.32M | 51.80M | 90.67M | 325.49M | 26.14M | 16.12M | 11.43M | 9.72M | 15.44M | 1.12M |
| Book Value | 174.13M | 413.64M | 397.27M | 420.28M | 506.61M | 610.90M | 218.78M | 160.99M | 79.86M | 56.88M | 82.10M | (3.43M) |
| Return on Equity | -1.60 | -0.42 | -0.38 | -0.32 | -0.26 | -0.15 | -0.29 | -0.38 | -0.44 | -0.48 | -0.28 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.27M | 17.34M | 20.75M | 15.29M | 14.11M | 53.88M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (73.33M) | (81.00M) | (74.12M) | (66.12M) | (57.43M) | (19.22M) | (54.40M) | (50.84M) | (49.52M) | (42.79M) | (38.60M) | (37.17M) |
| EPS | -0.83 | -0.92 | -0.85 | -0.75 | -0.66 | -0.22 | -0.63 | -0.59 | -0.59 | -0.55 | -0.50 | -0.53 |
| Free Cash Flow | (85.98M) | 114.95M | (83.19M) | (30.23M) | (72.22M) | 268.76M | (43.44M) | (42.55M) | (48.93M) | (34.32M) | (29.05M) | (25.71M) |
| FCF / Share | -0.97 | 1.31 | -0.95 | -0.35 | -0.83 | 3.08 | -0.50 | -0.49 | -0.58 | -0.44 | -0.38 | -0.37 |
| Operating CF | (85.85M) | 117.27M | (80.63M) | (28.78M) | (71.93M) | 269.13M | (43.44M) | (42.53M) | (48.84M) | (34.31M) | (29.03M) | (25.62M) |
| Total Assets | 652.55M | 738.36M | 649.38M | 682.42M | 743.76M | 760.16M | 478.84M | 515.12M | 553.91M | 448.94M | 473.77M | 494.74M |
| Total Debt | 24.27M | 20.46M | 19.47M | 19.47M | 19.35M | 16.59M | 16.63M | 16.73M | 16.97M | 17.20M | 17.42M | 13.04M |
| Cash & Equiv | 39.08M | 149.10M | 95.29M | 81.95M | 51.27M | 224.46M | 49.48M | 45.18M | 41.51M | 37.32M | 28.74M | 49.12M |
| Book Value | 107.88M | 174.13M | 242.54M | 305.49M | 364.41M | 413.64M | 423.77M | 466.07M | 505.08M | 397.27M | 429.94M | 459.68M |
| Return on Equity | -0.68 | -0.47 | -0.31 | -0.22 | -0.16 | -0.05 | -0.13 | -0.11 | -0.10 | -0.11 | -0.09 | -0.08 |
KURA News
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcript
Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors